MY194040A - Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases - Google Patents

Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases

Info

Publication number
MY194040A
MY194040A MYPI2017001041A MYPI2017001041A MY194040A MY 194040 A MY194040 A MY 194040A MY PI2017001041 A MYPI2017001041 A MY PI2017001041A MY PI2017001041 A MYPI2017001041 A MY PI2017001041A MY 194040 A MY194040 A MY 194040A
Authority
MY
Malaysia
Prior art keywords
binding protein
antibodies
inflammatory diseases
disorders
present
Prior art date
Application number
MYPI2017001041A
Other languages
English (en)
Inventor
Eduardo Schiffrin
Val Greg Del
Original Assignee
Ab2 Bio Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab2 Bio Sa filed Critical Ab2 Bio Sa
Publication of MY194040A publication Critical patent/MY194040A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
MYPI2017001041A 2015-03-05 2016-03-03 Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases MY194040A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15157742 2015-03-05
EP15158781 2015-03-12
EP15186626 2015-09-24
PCT/EP2016/054524 WO2016139297A1 (en) 2015-03-05 2016-03-03 Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases

Publications (1)

Publication Number Publication Date
MY194040A true MY194040A (en) 2022-11-09

Family

ID=55453181

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017001041A MY194040A (en) 2015-03-05 2016-03-03 Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases

Country Status (17)

Country Link
US (4) US10882905B2 (enExample)
EP (1) EP3265807A1 (enExample)
JP (2) JP7274259B2 (enExample)
KR (1) KR102511343B1 (enExample)
CN (1) CN107660150B (enExample)
AU (1) AU2016227644B2 (enExample)
CA (1) CA2972689A1 (enExample)
CL (1) CL2017002237A1 (enExample)
CO (1) CO2017008940A2 (enExample)
IL (1) IL253292B2 (enExample)
MX (1) MX2017010919A (enExample)
MY (1) MY194040A (enExample)
PH (1) PH12017501402A1 (enExample)
RU (1) RU2755691C2 (enExample)
SG (1) SG11201706879UA (enExample)
UA (1) UA128752C2 (enExample)
WO (1) WO2016139297A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014317035B2 (en) * 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
SG11201706879UA (en) 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
CA3047833A1 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
WO2019051015A1 (en) 2017-09-06 2019-03-14 Yale University VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE
JOP20200216A1 (ar) * 2018-03-05 2020-09-03 Janssen Pharmaceutica Nv تجارب للكشف عن التنكس العصبي
WO2020018364A1 (en) * 2018-07-16 2020-01-23 University Of Hawaii Anti-galectin-9 antibody and methods of use thereof
CN108929382B (zh) * 2018-07-20 2019-10-15 深圳市第三人民医院 一种抗serinc5的抗体及其应用
EP3892300A4 (en) 2018-12-03 2022-12-14 Mabprotein Co.,Ltd. ANTIBODIES RECOGNIZING A NEO-EPITOPE OF ACTIVATED INTERLEUKIN-18 PROTEINS AND ASSOCIATED APPLICATION
JP7631203B2 (ja) * 2019-01-18 2025-02-18 ユニバーシティ ヘルス ネットワーク Ｌｉｌｒｂ３結合分子とその使用
US20220296707A1 (en) * 2019-06-04 2022-09-22 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
CN112582058B (zh) * 2019-11-07 2022-04-01 广州医科大学 一种基于空气质量的慢阻肺发病预测方法及系统
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
CN116323654A (zh) * 2020-06-01 2023-06-23 阿瓦洛医疗公司 涉及il-18的抗体的方法及疗法
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
CA3201637A1 (en) 2020-11-18 2022-05-27 Novartis Ag Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
WO2023121643A1 (en) * 2021-12-20 2023-06-29 Avalo Therapeutics, Inc. Methods and treatment for adult-onset still's disease and systemic-onset juvenile idiopathic arthritis involving antibodies to il-18
CN117279950B (zh) * 2022-01-28 2025-08-08 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
EP4486367A1 (en) 2022-03-04 2025-01-08 AB2 Bio SA Il-18 binding protein (il-18bp) in the treatment of vexas
JP2025509832A (ja) * 2022-03-15 2025-04-11 コンピュジェン リミテッド Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用
EP4646270A2 (en) 2023-01-06 2025-11-12 Alector LLC Anti-il18 binding protein antibodies and methods of use thereof
CN120530131A (zh) 2023-01-06 2025-08-22 拉森医疗公司 抗il-18bp抗体
CN119241693B (zh) * 2024-09-29 2025-05-27 华中农业大学 一种抗犬瘟热病毒的基因工程嵌合抗体及应用
CN119192356B (zh) * 2024-09-29 2025-05-27 华中农业大学 识别犬瘟热病毒h蛋白的单克隆抗体、检测试纸条及应用
CN120349409A (zh) * 2025-04-08 2025-07-22 生物岛实验室 Il-18bp纳米抗体及其制备方法与应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
SG63617A1 (en) 1991-01-18 1999-03-30 Amgen Boulder Inc Methods for treating tumar necrosis factor mediated diseases
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
WO1996013590A2 (en) 1994-10-21 1996-05-09 Innogenetics N.V. New sequences of hepatitis c virus genotypes and their use as prophylactic, therapeutic and diagnostic agents
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
EP1110969A4 (en) * 1998-09-01 2002-01-09 Hayashibara Biochem Lab INTERLEUKIN 18-BINDING PROTEINS
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
DK1257292T3 (da) * 2000-02-21 2011-07-18 Merck Serono Sa Anvendelse af IL-18-inhibitorer
ES2365600T3 (es) * 2000-02-21 2011-10-07 Merck Serono Sa Uso de inhibidores de il-18.
KR100798545B1 (ko) 2000-05-05 2008-01-28 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 죽상경화증의 치료 또는 예방을 위한 ｉｌ-18 저해물질의용도
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
CA2634294A1 (en) 2000-08-03 2002-02-14 Therapeutic Human Polyclonals, Inc. Production of humanized antibodies in transgenic animals
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
ATE380558T1 (de) * 2001-01-29 2007-12-15 Serono Lab Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
US20030008822A1 (en) 2001-05-16 2003-01-09 Charles Dinarello Use of IL-18 inhibitors for the treatment or prevention of sepsis
HRP20030842B1 (hr) 2001-05-25 2017-06-02 Ares Trading S.A. UPOTREBA IL-18 INHIBITORA ZA LIJEČENJE I PREVENCIJU OZLJEDA CNS-a
RS51755B (sr) * 2002-03-22 2011-12-31 Laboratoires Serono Sa. Korišćenje inhibitora il-18 za lečenje i/ili prevenciju perifernih vaskularnih bolesti
BR0315155A (pt) * 2002-10-08 2005-08-16 Ares Trading Sa Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
BRPI0408246A (pt) 2003-03-11 2006-03-01 Applied Research Systems vetores de expressão que compreendem o promotor ie2 do mcmv
US20080076708A1 (en) 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
AU2011224023C1 (en) 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
WO2005087249A1 (ja) 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
WO2006085983A2 (en) 2004-07-09 2006-08-17 University Of North Carolina At Chapel Hill Viral adjuvants
AU2005277404A1 (en) 2004-08-20 2006-03-02 Smithkline Beecham Corporation Methods of healing wounds by administering human IL-18
PL2267024T3 (pl) 2005-06-03 2012-10-31 Ares Trading Sa Wytwarzanie rekombinowanego białka wiążącego IL-18
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1924710B1 (en) 2005-09-15 2011-03-30 Val-Chum, S.E.C. Methods of diagnosing ovarian cancer
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US9255144B2 (en) * 2010-12-20 2016-02-09 Medimmune Limited Anti-IL-18 antibodies and their uses
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
AU2014317035B2 (en) * 2013-09-05 2020-02-27 Ab2 Bio Sa IL-18 binding protein (IL-18BP) in inflammatory diseases
SG11201706879UA (en) 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases

Also Published As

Publication number Publication date
RU2755691C2 (ru) 2021-09-20
JP2018513116A (ja) 2018-05-24
US11926663B2 (en) 2024-03-12
NZ733897A (en) 2023-11-24
AU2016227644B2 (en) 2022-06-16
RU2017134857A3 (enExample) 2019-12-23
IL253292B2 (en) 2023-05-01
CA2972689A1 (en) 2016-09-09
BR112017017076A2 (pt) 2018-04-10
SG11201706879UA (en) 2017-09-28
US20200377586A1 (en) 2020-12-03
US11820817B2 (en) 2023-11-21
IL253292A (en) 2017-09-28
KR102511343B1 (ko) 2023-03-17
EP3265807A1 (en) 2018-01-10
KR20170121199A (ko) 2017-11-01
CN107660150A (zh) 2018-02-02
US20210188968A1 (en) 2021-06-24
CO2017008940A2 (es) 2017-11-10
US20240190952A1 (en) 2024-06-13
CN107660150B (zh) 2023-10-24
JP7274259B2 (ja) 2023-05-16
AU2016227644A1 (en) 2017-07-20
US10882905B2 (en) 2021-01-05
WO2016139297A1 (en) 2016-09-09
UA128752C2 (uk) 2024-10-16
CL2017002237A1 (es) 2018-03-09
MX2017010919A (es) 2017-12-07
RU2017134857A (ru) 2019-04-09
IL253292B1 (en) 2023-01-01
PH12017501402A1 (en) 2018-01-15
JP2021176860A (ja) 2021-11-11
US20180127494A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
PH12017501402A1 (en) Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
PH12016500425A1 (en) Il-18 binding protein (il-18bp) in inflammatory diseases
PH12016501644A1 (en) Binding proteins and methods of use thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
ZA201801083B (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
ZA201803661B (en) Compositions and methods for decreasing tau expression
MY188183A (en) Antibodies to alpha-synuclein and uses thereof
PH12018500578A1 (en) Methods of treating inflammatory diseases
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
MX2023003519A (es) Anticuerpo anti-semaforina 4d humano.
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
WO2017019957A3 (en) Binding proteins and methods of use thereof
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12019500434A1 (en) Anti-gm-csf antibodies and uses thereof